APO-CAL 250
Natural health product licensed in Canada
- Other names
- APO-CAL 250 mg, CAL 250 mg, CALCIUM 250 mg
- Licence holder
- Apotex Inc.
- NPN or DIN-HM
- 00682047
- Status
- Active licence
- Licence date
- 12 August 2008
- Revision date
- 6 November 2009
- Form
- Comprimé enrobé
- Route of administration
- Orale
- Application type
- DIN de transition
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Croscarmellose de sodium, Carbowax, Eau purifiée, Hypromellose, Dioxyde de titane, Quinoline Yellow WS, Bleu brilliant FCF, sulfate sodique de lauryle, Stéarate de magnésium, Poly(dextrose)
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | minimum: 1 Comprimé ; maximum: 2 Comprimé | minimum: 1 Tous les jours ; maximum: 3 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps in the development and maintenance of bones and teeth.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
In mild hypercalcemia and (exceeding 300 mg/24 hours) as well as in chronic renal failure, or where there is evidence of stone formation in the urinary tract, adequate checks must be kept on urinary calcium excretion. If necessary, the dosage should be reduced or calcium therapy discontinued.
- Contre-indications
Hypercalcemia and hypercalciuria (e.g. hyperparathyroidism, vitamin D overdosage, decalcifying tumors such as: Plasmocytoma; bone metastases); severe renal or cardiac disease; and in calcium loss due to immobilization.
Source
Official Health Canada record, licence 00682047
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2009. Photograph the packaging to check whether it has changed. Photograph the packaging